Private Advisor Group LLC Invests $30,000 in CureVac (NASDAQ:CVAC)

Private Advisor Group LLC acquired a new stake in CureVac (NASDAQ:CVAC) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,236 shares of the company’s stock, valued at approximately $30,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC grew its stake in shares of CureVac by 26.9% in the third quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock worth $82,000 after acquiring an additional 5,927 shares during the period. Green Alpha Advisors LLC boosted its holdings in CureVac by 41.3% in the third quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock worth $80,000 after purchasing an additional 7,979 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in CureVac in the 2nd quarter worth approximately $54,000. Vanguard Personalized Indexing Management LLC raised its stake in CureVac by 99.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock valued at $147,000 after buying an additional 21,999 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of CureVac during the 2nd quarter valued at $108,000. 17.26% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 price target on shares of CureVac in a research note on Monday, September 16th.

CureVac Stock Performance

NASDAQ CVAC opened at $2.84 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.28 and a current ratio of 2.29. CureVac has a 12 month low of $2.21 and a 12 month high of $6.30. The company’s 50 day moving average is $2.95 and its two-hundred day moving average is $3.25.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. The firm had revenue of $15.55 million for the quarter, compared to the consensus estimate of $10.07 million. As a group, equities research analysts expect that CureVac will post 0.05 EPS for the current fiscal year.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.